This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

Zymergen Inc.
11/3/2021
Thank you for standing by, and welcome to the Zymergen Third Quarter 2021 Financial Results Conference Call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during that time, simply press star 1 on your telephone. If you require any further assistance, please press star 0. I will now turn the call over to Mr. Mike Doolin. Please begin.
Thank you all for joining. Earlier today, Zymergen released preliminary financial results for the quarter ended September 30th, 2021. If you haven't received this news release, or if you'd like to be added to the company's distribution list, please send an email to investors at zymergen.com. Joining me today from Zymergen are Jay Flatley, Acting Chief Executive Officer, and Ina Singh, Chief Financial Officer. Before we begin, I'd like to remind you that management will make statements during this call that are forward-looking statements within the meaning of the federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated. Additional information regarding these risks and uncertainties appears in the section entitled Forward-Looking Statements in the press release Zymergen issued today. For more complete list and description, please see the risk factors section of the company's latest 10Q and other filings with the Securities and Exchange Commission, including when filed the Form 10Q for this quarter. Except as required by law, Zymergen disclaims any intention or obligation to update or revise any financial or product pipeline projections or other forward-looking statements, whether because of new information, future events, or otherwise. This conference call contains time-sensitive information that is accurate only as of the live broadcast, November 3rd, 2021. In addition, please note that the third quarter financial results discussed today are preliminary and estimated and are subject to the completion and finalization of Zymergen's financial and accounting closing procedures. With that, I'd like to turn the call over to Jay.
Thanks, Mike, and thank you all for joining us this afternoon. On today's call, I'll begin with an update on our progress against the objectives we set in August. I'll then turn the call over to Ina for a more detailed review of our financials, including our preliminary third quarter results and our forecasted cash burn. In addition to the summary of the work we've done to date, I'll share a high-level overview of our forward-looking portfolio. This will provide a general sense of our direction, but is not intended to provide full details as our work is ongoing. We expect to complete our strategic plan around year-end and will be in a position to provide more detailed plans once that work is complete. In our business update in August, we committed to complete a number of key deliverables over the several subsequent quarters, including a full reexamination of the company's target markets, confirming our past views or altering them if the data indicate a shift in market focus is appropriate, including exploring potential new markets. A plan to reduce the company's burn rate to extend our operating runway. A deep dive into the process by which we prepare and launch products to be sure they are market ready and can be easily integrated into our customers' workflows. A plan to strengthen our commercial team and ensure the reliability and robustness of both our sales pipeline and forecast processes. And lastly, a multi-year plan with clear milestones and goals that the company can be held accountable to achieving. Over the last 90 days, we've made significant progress towards these goals. Working with top-tier consultants, we've done a deep dive on our market opportunities and our portfolio, using a standardized process to assess our investments. This included overall market size, our addressable market, competitive profiles, product development cost, cost of goods of the ultimate product, cost of customer acquisition, time to market, margin profile, and development risk, all the factors you'd expect to consider in building an optimized pipeline. We stopped work on a number of programs and promoted several others. These changes allowed us to implement a reduction in force of approximately 220 positions across a variety of levels and functions. We believe these tough decisions, along with a reduction in related overhead spending, will lower our burn rate sufficiently to operate to mid-2023 with the cash we have on hand. We've established a rigorous product development process to move products from concept to launch in a consistent and systematic way, which will ultimately help ensure greater confidence in product success. We've also restructured our commercial team with a more customer-centric orientation, integrating the formerly separate marketing function to drive a holistic lead to revenue process. In addition, we've more clearly defined our sales operations function to increase discipline in how we engage customers. With our portfolio and cost reduction work largely in place, we've kicked off our process to develop a comprehensive strategic plan that maps the business through 2024. Let me now share some additional details. Our portfolio review indicated that we were working on at least 30 different programs, far too many to adequately resource. It was imperative that we narrow our focus to a smaller number that we believe capitalize on our strengths and provide clear commercial opportunities. That resulted in decisions to pause or eliminate several programs while promoting others to a higher level of investment. A critical highlight is the cancellation of two programs that were prominent in our public plans, Hyline, known as ZYM-102, and our direct-to-consumer insect repellent, referred to as ZYM-201. In the case of Hyline Films, we no longer have conviction in the market opportunity. To be clear and contrary to many published reports, The product worked as designed. The underlying technology and science are sound. The technical issues that I discussed on our August call caused delays, but were quickly resolved by our teams and were not a factor in our decision to halt the project. In fact, at the time we canceled the program, we had made tens of thousands of square meters of hylene. The issues we uncovered were commercial. We looked more closely at the foldable display market. and the emerging data on the market segment that we targeted with Hyline and other electronic films indicated a smaller near-term opportunity than we initially expected. As a result, we stopped work on our electronic films programs, but are continuing work on our ZYM 101 film in partnership with Sumitomo. We will also continue to explore and develop bio-based polyimids in several different form factors, which we expect will add value to potential future products, not just in electronics, but other markets as well. In the case of our insect propellant and other consumer care programs, our review showed that the cost of customer acquisition with a direct-to-consumer model would have been prohibited for Zymogen. While the product performance was satisfactory, it could not be produced and distributed at a price point competitive with the incumbent products. With this assessment, we've decided to park all our efforts in consumer care. We have, however, developed strong IP and technology around bioactives and remain open to potential future partnerships in clean consumer care. Turning now to the forward-looking portfolio, we continue to see success with our work in agriculture, particularly with a flagship program on nitrogen fixation, where we're working with an important partner. We expect to have data later this year on the performance of our microbes in both corn and wheat field trials across over 50 sites in North America. We're also accelerating work on two programs in the healthcare market, one for development of key enzymes used in vaccine production, and a second in drug discovery. Our enzyme work is focused on improving both supply and performance for next generation vaccines, and our team's deep enzymology experience is enabling us to quickly develop several enzymes for potential use in vaccine manufacturing. In drug discovery, the size and diversity of our metagenomic libraries provide the raw materials to discover molecules that can modulate important oncology and other validated targets. We believe we have a powerful methodology to discover and unlock the potential of millions of natural products that are currently considered unreachable using traditional drug discovery techniques. We expect to be in a position to share data on this program in the coming months. Additionally, we have programs that are in the early concept stage being evaluated for market size, product development costs, time to market, development risk, and the other criteria that I described earlier. In some cases, these programs may be funded to move into full development, or they might be parked and protected for potential development in the future when resources are available to commit to them. Lastly, we've reorganized our research group around what we call Leads and Seeds. Leads are the potential drug targets that I just spoke of, and seeds are the early exploratory ideas that, if viable, will be funded to fuel our future development pipeline. The key takeaway is that we focused our investments, restructured our development and research processes, and now have a pipeline of products that we believe capitalize on our capabilities and provide clear commercial opportunities. As you would expect, These portfolio updates have resulted in a number of changes to our organization and leadership structures, which I'd like to take you through now. A key element to ensuring that we're set up for long-term success is to have the best possible leadership. We're laser focused on ensuring that we have the right team to execute our product development and operation plans, efficiently bringing products to market, and positioning Zymergen as a stronger company with a compelling operating plan. As I mentioned in our last call, we've added several key executives who have been instrumental in our recent work. In addition, we've made some key changes to our structure that streamline our organization with a clear focus on accelerating product development and commercialization. Notably, we've centralized our strategy, business development, and portfolio management into a single organization to drive rigor in our product development process, combining groups that had previously been spread across the company. In addition to these changes, Jed Dean, one of Zymergen's co-founders, has decided to move on from the company after completing a smooth transition of his responsibilities to Sibod Deshmukh, who joined us in July. Jed's last day with us was October 31st. We're all grateful for Jed's vision in his work in advancing the Zymergen mission and thank him for his many contributions. Before I turn the call over to Ina, I want to reemphasize a key point. The technology platform, EdzimerGen, works as advertised. We believe we have the world's largest metagenomics library, a library which has potential applications in agriculture, healthcare, and consumer care. We've begun to explore these capabilities through partnerships in the agriculture space and are excited to pursue further applications. Our proprietary early discovery and screening capabilities allow us to identify relevant biomolecules for a variety of use cases, such as novel therapeutics for challenging targets and agricultural applications. As an example, just last week, a paper was published in Nature Communications that highlighted the work we performed with Synlogic to improve their synthetic biotic medicine using our biosensor-enabled enzyme engineering. We've continued to review our technology platform with external experts and scientists and remain confident in the capabilities of our platform. With that, I'll turn the call now over to Ina for more details on our financials. Ina?
You're reading a preview of the ZY Q3 2021 earnings call.
Free account.